Loading clinical trials...
Loading clinical trials...
CRIZOTINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED CRIZOTINIB CLINICAL STUDIES
Conditions
Interventions
crizotinib
Locations
13
China
Cancer Hospital Chinese Academy of Medical Science
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Fujian Province Oncology Hospital
Fuzhou, Fujian, China
Sun Yat-Sen University Cancer center
Guangzhou, Guangdong, China
The First Affiliated Hospital of Guangzhou Medical University.
Guangzhou, Guangzhou, China
Jilin Cancer Hospital
Changchun, Jilin, China
Start Date
December 27, 2021
Primary Completion Date
March 21, 2028
Completion Date
March 21, 2028
Last Updated
March 30, 2026
NCT06043817
NCT07363252
NCT06758401
NCT06476808
NCT07528066
NCT06253871
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions